Navigation Links
STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
Date:8/26/2009

    PARIS, August 26 /PRNewswire-FirstCall/ --
    - Net Profit Up 11%
    - Strong Research and Investment Effort
    - Positive net Financial Position
    - Annual Growth Guidance Maintained at 10%

The Board of Directors, meeting on 25 August 2009 under the chairmanship of Albert Saporta approved the 2009 half year financial statements:

    In million Euros         H1 2008      08/07      H1 2009
                                    %CA   Var.%             %CA
    Sales                87.0      100.0  16     97.6      100.0

    Cost of goods sold  (19.9)     (22.8) 18    (22.5)     (23.1)
    SG&A                (35.1)     (40.3) 12    (37.8)     (38.8)
    R&D net             (13.7)     (15.7) 22    (17.7)     (18.1)

    EBIT                 18.4       21.1  19     19.6       20.1
    Net result, group    12.0       13.8  19     13.4       13.7
    share

    EBITDA               21.5       24.8  14     24.1       24.7
    Capital expenditure  (4.9)      (5.6)(21)    (9.4)      (9.6)
    Free cash flow       10.0       11.5  43     14.5       14.8
    Net financial debts  4.2         4.9 (54)    (1.3)      (1.4)
    Equity               75.4       86.6  29     92.9       95.2

    EPS, diluted         0.90 EUR         19     1.01 EUR
    Dividend rate          39%         -1580%      35%
    Dividend per share   0.35 EUR         -      0.35 EUR


    (continued)

    In million Euros             09/08   B 2009   09/08   OL1 2009
                                 Var.%              %      Var.%
    Sales                        12     185.0     100.0   8       187.7

    Cost of goods sold           13     (44.2)    (23.9)  11      (44.4)
    SG&A                          8     (77.7)    (42.0)   7      (78.0)
    R&D net                      29     (34.2)    (18.5)  14      (36.3)

    EBIT                          7      29.0      15.6    3       29.0
    Net result, group share      11      19.6      10.6    3       19.7

    EBITDA                       12      37.5      20.2   56          -
    Capital expenditure          93     (21.6)    (11.7) 130          -
    Free cash flow               45       4.9       2.6  (66)         -
    Net financial debts        (131)      9.5           (818)         -
    Equity                       23     109.0             17          -

    EPS, diluted                 11      1.47 EUR          3       1.48 EUR
    Dividend rate             -1017%       34%        8              34%
    Dividend per share           -       0.50 EUR         11       0.50 EUR

Sales growth and financial position

In spite of the unfavourable economic background, sales were maintained at a high level (up 12% - 11% organic, excluding foreign exchange effect), due to the continuing growth of sublingual treatments. The launch of ORALAIR(R), which started at the end of 2008 in Germany, has confirmed its commercial success.

Selling, general and administrative expenses posted a moderate 8% increase, substantially offset by the growth in sales. The 29% increase in net R&D costs highlighted the continued dynamic development of allergen tablets. In this context, operating profit grew by 7% to EUR 19.6 million. Due to good control of financial expenses, net profit increased by 11% to EUR 13.4 million. Diluted earnings per share amounted to EUR 1.01.

EBITDA grew by 12% to EUR 24.1 million. Against a background of sustained investments, free cash flow rose by 45% to a positive EUR 14.5 million, particularly due to a reduction in working capital requirements. For the first time in 10 years, the net financial position was a positive EUR 1.3 million.

The half-year financial report can be downloaded from the corporate website: http://www.stallergenes.com

Significant recent transactions and events

The mutual recognition procedure for Oralair(R) (grass pollen desensitization tablet) started at an operational level in the second quarter and should lead to registration in most European countries by the end of 2009.

The phase IIb/III clinical study on the dust mite desensitization tablet for adult rhinitis proved positive and will support a European registration process. This study is a world first in dust mite immunotherapy, both in terms of its scale and the quality of its results.

Outlook for 2009

The 2009 sales growth guidance remains set at 10%. This level of growth should ensure operating profit remains at a level equivalent to 2008, against a background of increased R&D investments. Investments will remain at a high level, without calling into question the target of maintaining operating profitability above 15% and a positive free cash flow.

Lastly, the second half-year will be marked by a number of significant announcements. Five major phase II/III clinical study results are expected, of which three, if proving positive, will allow for registration into Oralair(R) phase III in the US, 3rd year of Oralair(R) long-term study in Europe and phase III Staloral(R) study on asthma in China.

ABOUT STALLERGENES

Stallergenes is a European biopharmaceutical company dedicated to desensitization therapies for the prevention and treatment of allergy-related respiratory diseases, e.g. rhinoconjunctivitis and allergic asthma. A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes 21% (gross) of its sales to Research and Development and is actively involved in the development of a new therapeutic class: sublingual desensitization tablets.

In 2008, Stallergenes had sales of EUR 171 million and provided desensitization treatments to more than 500,000 patients.

    Euronext Paris (Compartment B)
    Component of SBF 120
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

Additional financial information is available at: http://www.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
2. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
3. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
4. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
5. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
6. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
7. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
8. STALLERGENES: 2008: Strong Performance
9. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
10. BIO International Convention 2009: Research Location Germany Presents Potential in Regenerative Medicine
11. Jatrophaworld Training 2009: 2nd Generation nonfood Biofuel crops Knowledge Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Information Management Services ( ... The upgrade represents a completely new technical foundation and is so significant it ... responsive design interface, significantly increased speed for search results, a streamlined layout and a ...
(Date:2/8/2016)... Stockton has an active R&D program for the ... area, the Group has a unique research and development center ... in developing Bio Control products. Stockton ... parameters and regulatory guidelines, and is active in more than ... Stockton,s flagship product Timorex Gold ...
(Date:2/6/2016)... , ... February 06, 2016 , ... ... , The Center for Excellence in Education Sponsors Teacher Training Program , ... February 4, 2016 – The Center for Excellence in Education (CEE) will sponsor ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology:
(Date:1/18/2016)... 2016  Extenua Inc., a pioneering developer of ... and access of ubiquitous on-premise and cloud storage, today ... Cyber.  ... C4ISR and Cyber initiatives in support of National ... technology solutions," said Steve Visconti , Extenua ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
(Date:1/8/2016)... MANCHESTER, United Kingdom , Jan. 8, 2016   ... diagnostic products, today announced the closing of a $9 million ... Proceeds from the financing will be used to accelerate the ... for detecting early-stage pressure ulcers. United ... receiving CE Mark approval. The device,s introduction has been met ...
Breaking Biology News(10 mins):